CorMedix Therapeutics公布Rezzayo®预防异基因造血干细胞移植患者侵袭性真菌病的三期RESPECT试验积极顶线结果

美股速递04-27

CorMedix Inc. (CRMD) 宣布，其评估Rezzayo®用于预防异基因造血干细胞移植患者侵袭性真菌病的三期RESPECT临床试验，已获得积极的顶线结果。

该试验达到了其主要疗效终点，数据显示Rezzayo®在预防侵袭性真菌病方面表现出显著优势。此项积极结果为该药物在此高风险患者群体中的应用提供了强有力的支持。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1173394929?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-27 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173394929","market":"us","top_or_hot":-1,"title":"CorMedix Therapeutics公布Rezzayo®预防异基因造血干细胞移植患者侵袭性真菌病的三期RESPECT试验积极顶线结果","media":"美股速递","content":"<p>CorMedix Inc. (CRMD) 宣布，其评估Rezzayo®用于预防异基因造血干细胞移植患者侵袭性真菌病的三期RESPECT临床试验，已获得积极的顶线结果。</p>\n<p>该试验达到了其主要疗效终点，数据显示Rezzayo®在预防侵袭性真菌病方面表现出显著优势。此项积极结果为该药物在此高风险患者群体中的应用提供了强有力的支持。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix Therapeutics公布Rezzayo®预防异基因造血干细胞移植患者侵袭性真菌病的三期RESPECT试验积极顶线结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix Therapeutics公布Rezzayo®预防异基因造血干细胞移植患者侵袭性真菌病的三期RESPECT试验积极顶线结果\n</h2>\n\n<h4 class=\"meta\">\n\n2026-04-27 19:44 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CorMedix Inc. (CRMD) 宣布，其评估Rezzayo®用于预防异基因造血干细胞移植患者侵袭性真菌病的三期RESPECT临床试验，已获得积极的顶线结果。\n该试验达到了其主要疗效终点，数据显示Rezzayo®在预防侵袭性真菌病方面表现出显著优势。此项积极结果为该药物在此高风险患者群体中的应用提供了强有力的支持。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"","article_id":"1173394929","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173394929","pubTimestamp":1777290256,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CorMedix Inc. (CRMD) 宣布，其评估Rezzayo®用于预防异基因造血干细胞移植患者侵袭性真菌病的三期RESPECT临床试验，已获得积极的顶线结果。\n该试验达到了其主要疗效终点，数据显示Rezzayo®在预防侵袭性真菌病方面表现出显著优势。此项积极结果为该药物在此高风险患者群体中的应用提供了强有力的支持。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CRMD":"CorMedix Inc.","BK4007":"制药"},"translate_title":"CorMedix Therapeutics Announces Rezzayo ® Positive top-line results of the phase III RESPECT trial for the prevention of invasive mycosis in patients with allogeneic hematopoietic stem cell transplantation","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":1},"content_text":"CorMedix Inc. (CRMD) 宣布，其评估Rezzayo®用于预防异基因造血干细胞移植患者侵袭性真菌病的三期RESPECT临床试验，已获得积极的顶线结果。\n该试验达到了其主要疗效终点，数据显示Rezzayo®在预防侵袭性真菌病方面表现出显著优势。此项积极结果为该药物在此高风险患者群体中的应用提供了强有力的支持。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173394929","isCrawlerRequest":true}